Premature coronary artery disease is systematic lupus erythematosus with extensive reocclusion following coronary artery bypass surgery

Journal of Invasive Cardiology

Volumn 15, Issue 3, 2003, Pages 157-163

  D'Agate, David J ^a   Kokolis, Spyros ^a   Soloman, Nehad ^a   Belilos, Elise ^a   Carsons, Steven ^a   Andrieni, Julia ^a   Argyros, Thomas ^a   Glasser, Lynne A ^a   Dangas, George ^a  

^a NONE

Author keywords

Coronary artery disease; Systemic lupus erythematosus

Indexed keywords

ADULT; ANAMNESIS; ANGIOGRAPHY; ARTERY OCCLUSION; CASE REPORT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; DISEASE SEVERITY; EMERGENCY WARD; FEMALE; HEART PALPITATION; HUMAN; INCIDENCE; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MORBIDITY; MORTALITY; RIGHT CORONARY ARTERY; SAPHENOUS VEIN GRAFT; SURVIVAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX PAIN; TIME;

ADULT; ARTERIAL OCCLUSIVE DISEASES; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY BYPASS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; REOPERATION;

EID: 0037342684     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (50)

1. Urowitz MB, Bookman AA, Koehler B, et al. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976;60:221-225.
2. Jonsson H, Nived O, Sturfelt G. Outcome in systemic lupus erythematosus: A prospective study of patients from a defined population. Medicine 1989;68:141-150.
3. Petri M, Genovese M. Incidence of and risk factors for hospitalizations in systemic lupus erythematosus: A prospective study of the Hopkins Lupus Cohort. J Rheumatol 1992;19:1559-1565.
4. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham study. Am J Epidemiol 1997;145:408-415.
5. Heibel RH, O'Toole JD, Curtiss EI, et al. Coronary arteritis in systemic lupus erythematosus. Chest 1976;69:700-703.
6. Haider YS, Roberts WC. Coronary artery disease in systemic lupus erythematosus quantification of degrees of narrowing in 22 necropsy patients aged 16 to 36 years. Am J Med 1981;70:775-781.
7. Tsakraklides VG, Blieden LC, Edwards JE. Coronary atherosclerosis and myocardial infarction due to lupus erythematosus. Am Heart J 1974;87:637-641.
8. Kaplan SD, Chartash EK, Pizzarello RA, Furie RA. Cardiac manifestations of the antiphospholipid syndrome. Am Heart J 1992;124:1331-1338.
9. Takatsu Y, Hattori R, Sakaguchi K, et al. Acute myocardial infarction associated with systemic lupus erythematosus documented by coronary angiograms. Chest 1985;88:147-149.
10. Bonfiglio TA, Botti RE, Hagstrom JWC. Coronary arteritis, occlusion and myocardial infarction due to lupus erythematosus. Am Heart J 1972;83:153-158.
11. Petri M, Lakatta C, Magder L, et al. Effect of predinisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: A longitudinal data analysis. Am J Med 1994;96:254-259.
12. Fauci AS, Katz P, Haynes BF, Wolff SM. Cyclophosphamide therapy of severe necrotizing vasculitis. N Engl J Med 1979;301:235-238.
13. Haynes BF, Allen NB, Fauci AS. Diagnosis and therapeutic approach to the patient with vasculitis. Med Clin North Am 1986;70:355.
14. Petri M, Spence D, Bone LR, et al. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: Prevalence, recognition by patients, and preventative practices. Medicine 1992;71:291-302.
15. Manzi S, Selzer F, Sutton-Tyrrell K, et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999;42:51-60.
16. Ward MM. Premature morbidity from cardiovascular and cerebrovascular disease in women with systemic lupus erythematosus. Arthritis Rheum 1999;42:338-346.
17. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Myocardial infarction (MI) and stroke in SLE: Marked increased incidence after controlling for risk factors. Arthritis Rheum 1998;41(Suppl):S139.
18. Abu-Sharka M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol 1995;22:1259-1264.
19. Ilowite NT, Samuel P, Ginzler E, et al. Dysbetalipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum 1988;31:859-863.
20. Lahita RG, Rivkin E, Cavanagh I, et al. Low levels of total cholesterol, high-density lipoprotein, and apolipoprotein A1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1993;36:1566-1574.
21. Ettinger WH, Goldberg AP, Appelbaum-Bowden D, et al. Dysbetalipoproteinemia in systemic lupus erythematosus. Effect of steroids. Am J Med 1987;83:503-508.
22. Minick CR, Alonso DR, Rankin L. Role of immunologic arterial injury in atherogenesis. Thromb Haemost 1978;39:304-311.
23. Buckley BH, Roberts WC. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy: A study of 36 necropsy patients. Am J Med 1975;58:243-264.
24. Kalbak K. Incidence of arteriosclerosis in patients with rheumatoid arthritis receiving long-term corticosteroid therapy. Ann Rheum Dis 1972;31:196.
25. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992;93:513-519.
26. Axelrod L. Glucocorticoid therapy. Medicine 1976;55:39-65.
27. Moder KG, Miller TD, Tazelaar HD. Cardiac involvement in systemic lupus erythematosus (Review). Mayo Clinic Proc 1999;74:275-284.
28. Fukomoto S, Tsumagari T, Kinso M, et al. Coronary atherosclerosis in patients with systemic lupus erythematosus at autopsy. Acta Pathol Jpn 1987;37:1-9.
29. Dangas G, Mehran R, Harpel PC, et al. Lipoprotein (a) and inflammation in human coronary atheroma: Association with the severity of clinical presentation. J Am Coll Cardiol 1998;32:2035-2042.
30. Dangas G, Ambrose JA, D'Agate DJ, et al. Correlation of serum lipoprotein (a) with the angiographic and clinical presentation of coronary artery disease. Am J Cardiol 1999;83:583-585.
31. Petri M, Miller J, Ebert RF, et al. Lipoprotein (a) [Lp(a)] is predictive of myocardial infarction in SLE. Arthritis Rheum 1995;38(Suppl):S220.
32. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: An independent risk factor for vascular disease. N Engl J Med 1991;324:1149-1155.
33. Petri M, Roubernoff R, Dallal GE, et al. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996;348:1120-1124.
34. Homcy CJ, Liberthson RR, Fallon JT, et al. Ischemic heart disease in systemic lupus erythematosus in the young patient: Report of six cases. Am J Cardiol 1982;49:478-484.
35. Gould SE. Pathology of the Heart and Blood Vessels. Springfield Illinois, Charles C. Thomas, 1968: pp. 582-584.
36. Dangas G, Konstadoulakis MM, Epstein SE, et al. Prevalence of autoantibodies against contractile proteins in coronary artery disease and their clinical implications. Am J Cardiol 2000;85:870-872.
37. Gavaghan TP, Bebski V, Baron DW. Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery: A placebo controlled randomized trial. Circulation 1991;8:1526-1533.
38. Goldman S, Copeland J, Moritz T, et al. Starting aspirin therapy after operation: Effects on early graft patency. Circulation 1991;84:520-526.
39. Kabakov AE, Tertov VV, Saenko VA, et al. The atherogenic effect of lupus sera: Systemic lupus erythematosus-derived immune complexes stimulate the accumulation of cholesterol in cultured smooth muscle cells from human aorta. Clin Immunol Immunopathol 1992;63:214-220.
40. Wahl DG, Guillemin F, de Maistre E, et al. Risk of venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus. Lupus 1997;6:467-473.
41. Wu R, Nityanand S, Berglund L, et al. Antibodies to cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Atheroscler Thromb Vasc Biol 1997;17:3159-3163.
42. Mitzutani H, Kurata Y, Kosugi S. Monoclonal anticardiolipin autoantibodies established from (New Zealand white x BXSF)F1 mouse model of antiphospholipid syndrome cross-react with oxidized low-density lipoprotein. Arthitis Rheum 1995;38:1382-1388.
43. Vaarala O, Puurunen M, Lukka M. Affinity-purified cardiolipin-binding antibodies show heterogeneity in their binding to oxidized low-density lipoprotein. Clin Exp Immunol 1996;104:269-274.
44. Horkko S, Miller E, Dudi E. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. J Clin Invest 1996;98:815-825.
45. Palinski W, Horkko Miller E. Cloning of monoclonal antibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. J Clin Invest 1996;98:800-814.
46. Ames PRJ. Medical perspective on antiphospholipid antibodies, thrombosis and atherosclerosis in systemic lupus erythematosus: A unifying "membrane stress syndrome" hypothesis. Lupus 1994;3:371-377.
47. Love PE, Santoro SA. Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990;112:682-698.
48. Vaarala O, Manttari M, Manninen V, et al. Anticardiolipin antibodies and the risk of myocardial infarction in a prospective cohort of middleaged men. Circulation 1995;1:23-27.
49. Brown JH, Doherty CC, Allen DC, Morton P. Fatal cardiac failure due to cardiac microthrombi in systemic lupus erythematosus. Br Med J 1988;296:1505.
50. Kattwinkel N, Villanueva AG, Labib SB, et al. Myocardial infarction caused by cardiac microvasculopathy in a patient with the primary antiphospholipid syndrome. Ann Intern Med 1992;116:974-976.